You are here: Industry Insights > Tukysa

News List

UK grants marketing authorisation to “landmark” breast cancer therapy europeanpharmaceuticalreview
February 23, 2021
Seagen’s Tukysa® (tucatinib) was approved in the UK as part of a combination regimen for the treatment of adults with locally advanced or metastatic HER2-positive breast cancer.
Seattle Genetics and Merck Partner contractpharma
September 15, 2020
Seattle Genetics Inc. and Merck, known as MSD outside the United States and Canada, have announced two new strategic oncology collaborations.
Seattle Genetics gets approval of TUKYSA in Switzerland for metastatic HER2-positive breast cancer pharmaceutical-business-review
May 15, 2020
Seattle Genetics announced that the Swiss Agency for Therapeutic Products (Swissmedic) has granted approval for TUKYSA (tucatinib) tablets in combination with trastuzumab and capecitabine, for the treatment of patients with metastatic HER2-positive breast
Seattle Genetics gets FDA nod for breast cancer drug Tukysa pharmaceutical-business-review
April 22, 2020
Seattle Genetics has secured approval from the US Food and Drug Administration (FDA) for its Tukysa (tucatinib) to treat people with advanced unresectable or metastatic HER2-positive breast cancer.
FDA Approves Treatment Option for HER2-Positive Metastatic Breast Cancer americanpharmaceuticalreview
April 21, 2020
As part of Project Orbis, the U.S. Food and Drug Administration (FDA) approved Tukysa (tucatinib) in combination with chemotherapy (trastuzumab and capecitabine) for the treatment of ...